Evidence map›Paper›PMID 31953891›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2020

Allergen-specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy.

B Nothegger, N Reider, C E Covaciu, V Cova, L Ahammer, R Eidelpes, J Unterhauser, S Platzgummer, M Tollinger, T Letschka and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

B Nothegger *Department of Dermatology, Venerology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
N Reider *Department of Dermatology, Venerology and Allergology, Medical University of Innsbruck, Innsbruck, Austria.
C E CovaciuDepartment of Dermatology, Venerology and Allergology, Central Teaching Hospital, Bolzano/Bozen, Italy.
V CovaDepartment of Applied Genomics and Molecular Biology, Laimburg Research Centre, Ora, Italy.
L AhammerInstitute of Organic Chemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
R EidelpesInstitute of Organic Chemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
J UnterhauserInstitute of Organic Chemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
S PlatzgummerClinical Chemistry and Microbiology Laboratory, Tappeiner Hospital, Meran, Italy.
M TollingerInstitute of Organic Chemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
T LetschkaDepartment of Applied Genomics and Molecular Biology, Laimburg Research Centre, Ora, Italy.
K EisendleDepartment of Dermatology, Venerology and Allergology, Central Teaching Hospital, Bolzano/Bozen, Italy.ORCID https://orcid.org/0000-0002-8234-9964
Universität Innsbruck · ATBiomolecular Research Genomics (Italy) · ITInnsbruck Medical University · ATOspedale di Bolzano · ITKrankenhaus Meran · IT

Funding

European Regional Development Fund Interreg V-A Italy-Austria
6 · The paper itself

Abstract

backgroundMost birch pollen-allergic patients develop allergic cross-reactions to the major allergen found in apples Mal d1, known as pollen-related food allergy (prFA). This is due to a strong clinically relevant homology between the major allergen in birch Bet v 1 and Mal d 1. Daily apple consumption induces oral tolerance in prFA, but its effect on the inhalational allergy has not been investigated.

objectivesAs continuous apple consumption might also mitigate the inhalational allergy, this study aimed to uncover apple cultivars suitable for treatment of birch pollen rhinoconjunctivitis and apple allergy in a controlled and established dosage.

methodsPatients (n = 52) with birch pollen allergy and prFA to apples were subjected to a prick-to-prick test (SPT) with 23 cultivars (red-fleshed, old traditional and new commercial). By SPT, the apple parts flesh, peel equatorial and peel apical near the stalk were compared for their reactivity. One apple cultivar of each allergenicity class (low, middle and high) was subsequently tested in an oral provocation test (OPT).

resultsAccording to the SPTs, we provide a ranking of all 23 cultivars. Red-fleshed apples displayed the lowest reactivity, followed by old and new cultivars. Four cultivars showed disagreement from their allergenicity class: Santana and Pink Lady®, new cultivars that provoked only low to moderate. In contrast, White Rosemary and Goldparmäne, two old cultivars, induced strong reactions. Skin reactivity increased from flesh to peel to stalk, and SPT results could predict the severity of prFA of each allergenicity class.

conclusionsHerein, we propose a treatment protocol for allergen immunotherapy to birch pollen and prFA with daily apple consumption. Red-fleshed, old and the new cultivars Santana and Pink Lady® provoke less allergic reactions and are suitable for initial induction. After a controlled and well-tolerated increase of intake, also moderate and finally high allergenic apple cultivars should be integrated into treatment of birch pollen allergenic patients.

Indexed as

Food HypersensitivityMalusRhinitis, Allergic, SeasonalAllergensBetulaDesensitization, ImmunologicHumansImmunoglobulin ESkin TestsAllergensImmunoglobulin E

Identifiers

PMID31953891
PMCPMC7318684
OpenAlexW2998772426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.